Clinical trial Recruiting at 1 site Observational Ages 30 to 85

Examining the structure of dangerous brain plaques in stroke patients

Official title: Morphology of Advanced Symptomatic Cerebral Plaques With High Embolic Potential

Run by Chinese University of Hong Kong · NCT03291652 · Data updated 2026-11-12

This study is trying to find out if certain dangerous brain plaques in stroke patients can be identified using advanced imaging techniques to help prevent future strokes.

Quick facts

Study typeObservational
Ages30 Years to 85 Years
SexAll
Enrollment140 (estimated)
SponsorChinese University of Hong Kong
Academic / other
Locations1 site (Hong Kong)
StatusRecruiting
StartedFebruary 2010
Main results expectedDecember 23, 2026
Study endsDecember 31, 2027
Registry record updatedFebruary 24, 2026
Trial IDNCT03291652 on ClinicalTrials.gov

Is this trial a fit for you?

Likely a good fit

Ideal candidates are adults aged 30 to 85 with significant intracranial atherosclerotic stenosis and evidence of recent ischemic events.

Probably not a fit

Patients without significant intracranial stenosis or those who do not meet the age and clinical criteria may not benefit from this study.

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This observational study aims to identify unstable plaques in patients with intracranial atherosclerotic disease that pose a high risk for embolic events. Participants will undergo cranial MRI and MR angiography, followed by transcranial Doppler monitoring to detect microembolic signals. The analysis of angiograms will be conducted by investigators who are unaware of the patients' clinical backgrounds. Throughout the study, all participants will receive standard medical therapy.

Why it matters

Potential benefit: If successful, this study could lead to improved early detection of high-risk plaques, potentially reducing the incidence of ischemic strokes.

How similar studies have gone: While similar studies have explored plaque morphology, this specific approach focusing on high embolic potential in symptomatic patients is relatively novel.

Who can join: the full rules

Show full inclusion / exclusion criteria
Inclusion Criteria:

* Inclusion Criteria for the Symptomatic Group:

  1. Patient is 30 to 85 years of age, inclusive.
  2. Patients who have an acute infarct in diffusion-weighted MRI compatible with artery-to-artery thrombo-embolism, a relevant intracranial atherosclerotic stenosis ≥60%, and MES detected by TCD.
  3. Patient who has no contra-indication for the proposed imaging tests.
  4. Patient understands the purpose and requirements of the study, and has provided an informed consent.
* Inclusion Criteria for the Asymptomatic Group:

  1. Patient is 30 to 85 years of age, inclusive.
  2. Patient who has a high-grade (\>60%) intracranial stenosis (signal void in MR angiography) but without infarct in the corresponding vascular territory in DWI or T2-weighted sequence.
  3. Patient has no MES detected on TCD examination.
  4. Patient who has no contra-indication for the proposed imaging tests.
  5. Patient understands the purpose and requirements of the study, and has provided an informed consent.

Exclusion Criteria:

Subject who meets one or more of the following criteria cannot be recruited in the study:

1. Stroke etiology uncertain or unrelated to intracranial atherosclerosis, such as cardioembolism, Moyamoya disease, small vessel disease, etc.
2. A tandem stenosis \>50% at proximal internal carotid artery.
3. Bleeding propensity: active peptic ulcer disease, major systemic hemorrhage within 30 days, thrombocytopenia (platelets \<100 x 109/L), coagulopathy (INR \>1.5).
4. A medical condition that would not allow the patient to adhere to the protocol or complete the study.

Where it's running

  • Chinese University of Hong Kong
    Hong Kong, Hong Kong
    Recruiting

Study contacts

  • Principal investigator: Thomas Wai Hong LEUNG, FRCP — Chinese University of Hong Kong
  • Study coordinator: Thomas Wai Hong LEUNG, FRCP
  • Email: drtleung@cuhk.edu.hk
  • Phone: 852-35053593

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

How to take part

  1. Review the eligibility criteria above with your treating physician.
  2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
  3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.
Last reviewed 2026-11-14 by the Find a Trial editorial team. Information on this page is for educational purposes and is not medical advice. Always consult qualified healthcare professionals about clinical trial participation.